Drugs /

autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells

Autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells, 2 are phase 1 (2 open).

IL3RA Expression is the most frequent biomarker inclusion criterion for autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells clinical trials.

Acute myeloid leukemia is the most common disease being investigated in autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Autologous Cd123car-41bb-Cd3zeta-Egfrt-Expressing T Cells
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating autologous cd123car-41bb-cd3zeta-egfrt-expressing t cells and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cart123, anti-cd123 cart, cd123car-41bb-cd3zeta-egfrt-expressing t cells

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.